Conditions: Hypertension
Keywords: hypertension blood pressure LCZ696 dual-acting neprilysin nep inhibitor vasopeptidase angiotensin receptor ARNi Essential hypertension
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 389
Healthy volunteers: no

Brief summary:
This study is a phase 2 study in patients with essential hypertension.

Detailed description:

Arms:
arm 1: LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week. arm 2: LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week. arm 3: LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week. arm 4: Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.

Interventions: intervention 1: LCZ696 intervention 2: Placebo
Intervention descriptions: intervention 1: LCZ696 intervention 2: matching placebo to LCZ696

Protocol document: